Canada: Joint Actors And Tactical Pills: Securities Regulators Apply Canada's New Takeover Bid Regime To A Hostile Bid

Last Updated: April 17 2018
Article by Chat Ortved

Canada's takeover bid regime was overhauled in 2016, with the intention of rebalancing the dynamics among offerors, target boards, and target shareholders (the "New Takeover Regime"). The New Takeover Regime comprises three key elements:

  • bids must remain open for a minimum of 105 days (unless the target board reduces the period - to a minimum of 35 days - or enters into an "alternative transaction");
  • for a bid to succeed, more than 50% of the outstanding shares of the class that are subject to the bid, excluding shares owned by the bidder, must be tendered (the "Minimum Tender Condition"); and
  • bids must be extended for at least 10 days after satisfaction of the Minimum Tender Condition.

The New Takeover Regime was initially expected to have a meaningful impact on the hostile bid landscape in Canada, though it left potential offerors and the boards of potential target companies, as well as their advisors, with important questions. As the New Takeover Regime created significantly more risk for bidders, the incentive for bidders to focus their energies on friendly deals was expected to increase. At the same time, the regulators' tolerance for defensive tactics was expected to decrease, given the length of time boards would have to seek out better offers and the required shareholder support inherent in the new rules. In particular, while the New Takeover Regime did not result in any change to National Policy 62-202— Take-Over Bids—Defensive Tactics ("NP 62-202"), which is generally aimed at ensuring that shareholders are not denied the ability to make a fully informed decision about whether to tender to a takeover bid, it was expected that the new rules would vitiate the tactical poison pill, the primary tool used by target boards to defend against hostile bids prior to the changes, in almost all cases.

The orders of the Ontario Securities Commission (the "OSC") and its counterpart in Saskatchewan, the Financial and Consumer Affairs Authority (the "FCAA" and, together with the OSC, the "Commissions") in connection with Aurora Cannabis Inc.'s ("Aurora") takeover of CanniMed Therapeutics Inc. ("CanniMed"), along with their recently released joint reasons for those orders (the "Reasons"), shed light on the application of the New Takeover Regime. The Reasons generally offer the following lessons:

  • for bidders and targets, they confirm the expectation that regulators would defend their rebalancing of interests by enforcing the New Takeover Regime strictly;
  • for targets, they confirm that absent exceptional circumstances the regulators retain little patience for tactical poison pills, though questions remain as to how they will treat shareholder-approved rights plan that comply with proxy-advisor recommendations;
  • for bidders, properly drafted lock-up agreements - even "hard" lock-up agreements - are an important and acceptable element of the Canadian M&A landscape, though care should be taken to ensure these agreements do not result in "joint actor" status in the circumstances of the particular bid; and
  • at the same time, elements of the Reasons reflect a policy-driven approach, allowing flexibility for future transactions that may come before the Commissions. The diversity of fact patterns that emerge in the hostile takeover process can be expected to render an original analysis in every case.

Aurora's Bid for CanniMed

The facts leading to the Reasons are now quite well known. In November of 2017, certain large shareholders of CanniMed, two of whom had representatives on CanniMed's board of directors, disagreed with the board's decision to proceed with an acquisition of Newstrike Resources Inc. Rebuffed by the board, these shareholders entered into agreements with Aurora under which they agreed to tender to a takeover bid by Aurora. Importantly, these "lock-up agreements" were of the type commonly known as "hard" lock-up agreements, meaning that the shareholders would be required to tender to an Aurora bid even if a higher competing bid were to be made. Aurora then commenced a formal takeover bid. Aurora had been initially approached by a representative of the CanniMed shareholder without a seat on CanniMed's board, but it appeared to the Commissions that the locked-up shareholders had likely shared material undisclosed information amongst each other and with Aurora.

The Newstrike acquisition and the Aurora takeover were cast, at least by Aurora, as mutually exclusive, in that the Aurora bid was conditional on the Newstrike acquisition not proceeding. The CanniMed board, for its part, recommended a rejection of the Aurora bid and a vote in favour of the Newstrike acquisition and, to prevent Aurora acquiring an even greater blocking position, implemented a tactical poison pill (the "Rights Plan") that prevented Aurora from acquiring any further shares, or entering into any further lock-up agreements, whether "hard" or "soft".

Before the New Takeover Regime, the tactical dance of bidders and targets would inevitably culminate in a hearing before the applicable securities commission. The role of the regulators in this dance appears to be unchanged by the New Takeover Regime, though the timing and analysis will likely be different. Both Aurora and CanniMed sought orders from the Commissions, including to cease trade the Rights Plan, to grant relief from certain elements of the New Takeover Regime and to find that Aurora was acting jointly and in concert with the locked-up shareholders. The reaction of the Commissions to both parties' requests provide valuable guidance for potential bidders and potential targets on how the Commissions intend to enforce the New Takeover Regime, including the strict interpretation of some of its key provisions and the treatment of defensive tactics.

Poison Pills Under the New Takeover Regime

Since the 1980s, shareholder rights plans, commonly known as "poison pills", have been an integral part of the public M&A landscape in Canada. Over the years, public companies, major investors, securities regulators and proxy advisors had come to a common expectation of the structure and role of poison pills, and a long line of decisions by the provincial securities commissions had established that while poison pills would be tolerated for a reasonable amount of time to allow a target's board to seek a competing bid, they would ultimately be cease traded, usually after about 60 to 70 days.

The regulators' logic for this compromise arises from the principles expressed in NP 62-202, which generally are aimed at ensuring that shareholders are not denied the ability to make a fully informed decision about whether to tender to a takeover bid. In other words, in the context of takeover bids, the regulators are concerned with protecting shareholder choice.

Noting that prior poison pill decisions have little value in light of the New Takeover Regime, particularly since it was designed specifically "to provide sufficient time for other bids to surface without the need for Commission intervention to determine how long before a poison pill must be terminated," the Commissions cease traded the Rights Plan. The Commissions cited four elements of the Rights Plan as problematic, all of which interfered with the predictability of the New Takeover Regime:

  • its blocking of the exemption under the takeover bid rules that would allow Aurora to acquire up to an additional 5% of CanniMed through market purchases (the "5% Exemption");
  • its prevention of lock-up agreements, whether "hard" or "soft";
  • the fact that it replicated key requirements of the New Takeover Regime with variations in how those requirements could be satisfied, in a way that served "no useful purpose"; and
  • the fact that it deemed certain bidders to beneficially own shares of locked-up shareholders where those shareholders were not necessarily "joint actors" under the takeover bid rules.

The result was that the Rights Plan "had primarily a tactical motivation" and "could operate to deny CanniMed shareholders the potential benefits of the Aurora Offer," contrary to NP 62-202.

While the swift cease-trade of a tactical poison pill is not surprising under the New Takeover Regime, the Commissions' implicit endorsement of hard lock-ups adds a new element of uncertainty to the takeover landscape. Bidders should be encouraged that tactical rights plans that prevent hard lock-ups are more likely to be cease-traded. However, non-tactical, shareholder-approved rights plans that are compliant with proxy-advisor recommendations have long included provisions that separate "soft" from "hard" lock-ups, permitting the former and prohibiting the latter. Whether regulators will have more patience for these rights plans under future fact patters remains unclear; in the meantime, unless further notice follows from major investors (via proxy advisors or otherwise), it is not expected that public companies with rights plans in place will amend the long-accepted lock-up provisions, which are well-known to bidders, have been approved by shareholders and have the support of proxy advisors acting for major investors.

Exemptive Relief from the New Takeover Regime

Aurora asked the Commissions to shorten the 105-day bid period on the basis that the Newstrike transaction represented, in substance if not in form, an "alternative transaction" under the New Takeover Regime, a designation that would result in the bid period reducing to 35 days. At the same time, CanniMed asked the Commissions to deny Aurora access to the 5% Exemption.

The Commissions denied both applications, preferring to allow the New Takeover Regime to govern, without a clear justification on the facts for exemptive relief. The Commissions stated:

"Predictability of the regime, and particularly applicable time periods, is an important objective of take-over bid regulation and these reforms... Given the rebalancing that has occurred as a result of the amendments to the Canadian take-over bid regime, we are reluctant to make piecemeal changes to timing requirements that affect planning by bidders and target companies and that would make bid pricing and secondary market price determinations less predictable."

In the name of predictability, therefore, and on an analysis that showed that the policy rationale underlying the exception to the 105-day bid period in the face of an "alternative transaction" did not apply on these facts, Aurora was required to keep its bid outstanding for 105 days.

Similarly, the Commissions found no reason on the facts to disallow the 5% Exemption, noting that "the 5% exemption is an established feature of the Canadian take-over bid regime. Prohibiting the use of the 5% exemption may be appropriate in the public interest if the policies underlying the take-over bid regime are undermined by allowing its use. That is not the case here." Other facts, in other cases, presumably where shareholder choice could be adversely affected, may render a different result.

The Parameters of Acting Jointly or in Concert

Had the Commissions found that Aurora and the locked-up shareholders were acting jointly or in concert, significant regulatory impediments would have arisen for Aurora's bid. Not only would the bid have required a formal valuation and the other requirements for "insider bids", but the shares of the locked-up shareholders would have been excluded from the Minimum Tender Condition.

Acting jointly or in concert remains a question of fact, subject to provisions that deem or presume that certain actions confer or do not confer "joint actor" status. Ultimately, the key question is "whether the parties are acting together to bring about a planned result." CanniMed's special committee submitted that Aurora and the locked-up shareholders were joint actors on two bases: first, that the locked-up shareholders shared material non-public information with Aurora in a joint effort to effect the bid; and second, that hard lock-up agreements themselves, and the way they were negotiated, suggested joint action.

On the latter submission, the Commissions held that lock-up agreements are an established element of public acquisitions in Canada and that the joint actor provisions of the takeover bid rules do not distinguish between hard and soft lock-ups. However, they went further, noting that the increased deal risk to bidders under the New Takeover Regime may make the pursuit of lock-ups by bidders more necessary. In other words, the rebalancing of the regime appears to have re-balanced the acceptability of lock-ups as well, whether "soft" or "hard". As noted above, whether this affects major investors' support of traditional, shareholder approved rights plans that prevent hard lock-ups remains to be seen.

In addition, while the lock-up agreements contained voting provisions, the Commissions found that those provisions were directly related to the agreement to tender to the Aurora bid, and therefore did not confer joint actor status. This guidance will be helpful for bidders looking to craft compliant lock-up agreements in the future.

Whether the sharing of material non-public information created joint actor status involved a highly fact-based analysis in which the Commissions noted several problematic elements. Nonetheless, they found in the circumstances that in spite of possible improper activity by nominee directors, as a matter of corporate law, and possible improper use of material non-public information by various parties, only some of which would have been cleansed by disclosure, the Commissions determined that Aurora and the locked-up shareholders were not joint actors.

Conclusion

The Commissions have confirmed their commitment to the New Takeover Regime. Tactical poison pills will rarely be tolerated, exemptive relief will rarely be granted and the treatment of other elements of the takeover landscape, such as hard lock-up agreements, will be rebalanced commensurately with the regime itself. How that rebalancing will ultimately affect the fate of shareholder-approved rights plans remains to be seen. At the same time, the diversity of fact patterns that emerge in the hostile takeover process can be expected to render an original analysis in every case, and while the principles of the New Takeover Regime will be adhered to strictly, the regulators retain flexibility where shareholder choice is threatened.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Chat Ortved
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions